Calcineurin inhibitor nephrotoxicity
The use of the calcineurin inhibitors cyclosporine and tacrolimus led to major advances in the field of transplantation, with excellent short-term outcome
5–6
Potentially nonreversible nephrotoxicity of tacrolimus may lead to kidney graft loss and its diagnosis should be made after exclusion of any (Co/D) of Tacrolimus in renal transplant patients
Use of tacrolimus for initial immunosuppression in kidney transplant recipients has increased from 25
This study aimed to evaluate the safety of early initiation of tacrolimus in Calcineurin inhibitors mediate nephrotoxicity via a vaso-constrictive mechanism at the afferent glomerular arteriole, resulting in decreased renal blood flow and decreased glomerular filtration rate
However, as a potent CNI it has nephrotoxic potential leading to impaired renal function in some cases
Tacrolimus is the most widely used CNI after renal transplantation for immunosuppression
We present a case of a patient with a kidney transplant receiving maintenance immunosuppression with tacrolimus (FK506), mycophenolate mofetil, and prednisone who was treated with the recently approved antiviral medication Paxlovid (a combination of nirmatrelvir and ritonavir; Pfizer, New York, NY, USA) against SARS-CoV
Monitoring of whole blood trough levels of Evidence of rapamycin nephrotoxicity in kidney transplantation Randomized phase-III trials (US trial and global trial) conducted over 24 months and comprising almost 1300 renal allograft recipients treated with cyclosporin investigated the efficacy and safety of the concurrent administration of sirolimus in doses of 2 or 5 mg/day